Investment Analysts’ Recent Ratings Changes for Vanda Pharmaceuticals (VNDA)

Several analysts have recently updated their ratings and price targets for Vanda Pharmaceuticals (NASDAQ: VNDA):

• 1/5/2026 – Vanda Pharmaceuticals had its “buy” rating reaffirmed by analysts at UBS Group AG.
• 1/5/2026 – Vanda Pharmaceuticals had its price target raised by analysts at HC Wainwright from $20.00 to $22.00. They now have a “buy” rating on the stock.
• 1/3/2026 – Vanda Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/31/2025 – Vanda Pharmaceuticals had its price target raised by analysts at B. Riley from $11.00 to $14.00. They now have a “buy” rating on the stock.
• 12/31/2025 – Vanda Pharmaceuticals had its price target raised by analysts at Jefferies Financial Group Inc. from $5.00 to $7.50. They now have a “hold” rating on the stock.
• 12/17/2025 – Vanda Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 12/1/2025 – Vanda Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright.
• 11/28/2025 – Vanda Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/19/2025 – Vanda Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.